艾迪药业: 艾迪药业关于变更部分募集资金投资项目及金额调整的公告

Core Viewpoint - Jiangsu Aidi Pharmaceutical Co., Ltd. is adjusting its fundraising investment projects to enhance the efficiency of fund usage and expedite the development of advantageous projects, specifically by reallocating funds from the "Ustectidine New Indication Research Project" to the "Integrase Inhibitor Drug Research and Clinical Study Project" [4][8][14] Fundraising Investment Project Overview - As of June 20, 2025, the raw material drug production research and supporting facilities project has been completed, while other fundraising projects are ongoing [2] - The total amount of committed investment for the projects is 542.8 million yuan, with 396.6 million yuan invested by June 20, 2025 [3] Changes and Amount Adjustments - The company plans to change the name of the project "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" and adjust the investment amounts accordingly [4][5] - The remaining funds of 84.3699 million yuan from the original project will be fully allocated to the new project to meet its funding needs [6][9] Reasons for Changes - The original project faced delays due to stricter regulatory requirements and the need for further evaluations, prompting the company to reallocate funds to a project with more immediate needs [7][8] - The "Integrase Inhibitor Drug Research and Clinical Study Project" is crucial for the company's pipeline, aiming to develop a new generation of integrase inhibitors for HIV treatment [9][10] Impact of Changes - The adjustments are expected to improve the efficiency of fund usage and support the company's long-term development strategy without adversely affecting normal operations [12][14] - The project aims to enhance the effectiveness and safety of HIV treatments, aligning with national policy goals and expanding the company's product offerings [10][12] Approval Process - The board of directors and the supervisory board have approved the changes, which will be submitted for shareholder approval [13][14]